CurrentConnectiCarePolicy C5168-A

Lidocaine Patch Coverage Criteria

Customize your policy alerts

Sign up for ConnectiCare Policy C5168-A alerts

Get alerted when Policy C5168-A changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Pharmacy-benefit coverage and prior authorization for topical lidocaine patches used for post-herpetic neuralgia, cancer-related neuropathy, or diabetic neuropathy, including initial and continuation therapy.

Policy Summary

PayerConnectiCare

PolicyLidocaine Patch Coverage Criteria

Policy CodePolicy C5168-A

Change TypeNo material change

Effective DateMarch 13, 2026

Next Review DateJanuary 1, 2027

Key ActionBefore the requested product, document an adequate trial and failure of a preferred formulary topical therapy unless a qualifying allergy or contraindication applies.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Covered diagnosis categories

90Maximum patches per 30 days

6 monthsInitial authorization

12 monthsContinuation authorization

Topical

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentConnectiCarePolicy C5168-A

Lidocaine Patch Coverage Criteria

Customize your policy alerts

Sign up for ConnectiCare Policy C5168-A alerts

Get alerted when Policy C5168-A changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerConnectiCare

PolicyLidocaine Patch Coverage Criteria

Policy CodePolicy C5168-A

Change TypeNo material change

Effective DateMarch 13, 2026

Next Review DateJanuary 1, 2027

Key ActionBefore the requested product, document an adequate trial and failure of a preferred formulary topical therapy unless a qualifying allergy or contraindication applies.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Covered diagnosis categories

90Maximum patches per 30 days

6 monthsInitial authorization

12 monthsContinuation authorization

Topical

Route of administration

Coverage Criteria

Initial Therapy

Covered for initial therapy when all applicable criteria are met.

Initial therapy

Qualifying diagnosis: Post-herpetic neuralgia, cancer-related neuropathy, or diabetic neuropathy
Preferred topical therapy requirement: An adequate trial and failure of a preferred formulary topical dosage form, such as an OTC 4% patch, cream, or gel; OR a documented allergy or clinical contraindication to formulary products that is not expected with the requested product.
Additional ZTlido or Gen7T requirement: The member has tried and failed all formulary/preferred alternatives and generic non-formulary drugs with a matching indication before the requested therapy; OR has an FDA-labeled contraindication or serious side effects to all such alternatives, or they are likely to be less effective or cause harm; OR is currently receiving the requested medication and is at medical risk if therapy changes.
Apply only to ZTlido and Gen7T patches.

Continuation Therapy

Covered for continuation therapy when all criteria are met.

Continuation therapy

Safety and tolerability: No evidence of intolerable adverse effects or drug toxicity.
Clinical response: Positive clinical response demonstrated by improvement in pain.

Compendial Approved Off-Labeled Uses

The following compendial approved off-labeled uses are covered when the applicable criteria are met.

Compendial approved off-labeled use

Cancer-related neuropathy
Diabetic neuropathy

All other uses of lidocaine patch are considered experimental or investigational and are subject to the applicable off-label policy.

Lidocaine patch is excluded for members with hypersensitivity to lidocaine, any formulation component, or another amide-type local anesthetic.

Coding Information

HCPCSHCPCS

NA	DESCRIPTION

Provider Actions and Coverage Risks

Prior Authorization

Initial Authorization Required

Prior authorization is required for initial lidocaine patch coverage. Initial authorization is limited to 6 months.

Initial authorization duration: 6 months.

Prior Authorization

Continuation Authorization

Continuation authorization requires documentation that the member is tolerating therapy without intolerable adverse effects or drug toxicity and has demonstrated a positive clinical response. Continuation authorization is limited to 12 months.

Continuation authorization duration: 12 months.
Document tolerability and positive clinical response before requesting continuation.

Policy Background

Lidocaine patches are topical local anesthetics used to provide localized pain relief. The policy identifies post-herpetic neuralgia as an FDA-approved use for 5% patches and ZTlido; cancer-related neuropathy and diabetic neuropathy are identified as compendial approved off-label uses. OTC 4% and 3.5% patches are indicated for temporary relief of minor localized pain.

Definitions

Local anesthetic—topical

DefinitionA topical local anesthetic medication.

Drug classLocal anesthetic—topical

RouteTopical

Topical route of administration

DefinitionApplied to the skin or affected surface rather than administered systemically.

ApplicationApplied to the skin or affected surface

AdministrationNot administered systemically

Initial Therapy Criteria

Covered for initial therapy when all applicable criteria are met.

Initial therapy criteria

Qualifying diagnosis: The member has a diagnosis of post-herpetic neuralgia, cancer-related neuropathy, or diabetic neuropathy.
Preferred topical therapy trial or qualifying exception: The member has had an adequate trial and failed a preferred formulary topical dosage form, such as an OTC 4% patch, cream, or gel; OR has a documented allergy or clinical contraindication to formulary products that is not expected with the requested product.
Additional requirement for ZTlido or Gen7T: The member has tried and failed ALL formulary/preferred alternatives AND generic non-formulary drugs with a matching indication before use of the requested therapy; OR has an FDA-labeled contraindication or serious side effects to ALL such alternatives, or they are likely to be less effective or cause harm; OR is currently receiving the requested medication and is at medical risk if therapy changes.

Continuation Therapy Criteria

Continuation Criteria

Continuation coverage requires both tolerability and documented clinical benefit.

Continuation criteria

Tolerability and safety: The prescriber attests to, or the clinical reviewer has found, no evidence of intolerable adverse effects or drug toxicity.
Documented clinical benefit: Documentation shows a positive clinical response demonstrated by improvement in pain.

Step Therapy Requirements

Step	Requirement	Exception
1	Try and fail a preferred formulary topical dosage form before the requested product, such as an OTC 4% patch, cream, or gel.	A documented allergy or clinical contraindication to the formulary products that is not expected with the requested product.

Step	Applies to	Requirement	Exception
2	ZTlido and Gen7T patches only	Try and fail all formulary/preferred alternatives and generic non-formulary drugs with a matching indication before using the requested therapy.	The member has an FDA-labeled contraindication or serious side effects to all such alternatives; the alternatives are likely to be less effective or cause harm; or the member is currently receiving the requested medication and is at medical risk if therapy changes.

Preferred therapy	Indication
OTC 4% lidocaine patches	Pain relief only

Quantity Limits

Quantity limits

ProductLidocaine patches

Maximum quantity90 patches

Coverage period30 days

Site of Care and Administration

Note

Use the pharmacy benefit for home administration

Topical medications under this policy are recommended for pharmacy benefit coverage and patient self-administration at home.

Policy Summary

PayerConnectiCare

PolicyLidocaine Patch Coverage Criteria

Policy CodePolicy C5168-A

Change TypeNo material change

Effective DateMarch 13, 2026

Next Review DateJanuary 1, 2027

Key ActionBefore the requested product, document an adequate trial and failure of a preferred formulary topical therapy unless a qualifying allergy or contraindication applies.

SourceLink

On This Page

Preferred Topical Therapy Trial Required

Before requesting the product, document an adequate trial and failure of the preferred formulary topical dosage form, unless the member has a documented allergy or clinical contraindication to the formulary products that is not expected with the requested product.

Preferred topical options may include OTC 4% patches, cream, or gel.
Document the allergy or contraindication when a formulary trial is not appropriate.

Step Therapy

ZTlido and Gen7T Alternative Requirement

For ZTlido and Gen7T patches, document that the member tried and failed all formulary/preferred alternatives and generic non-formulary drugs with a matching indication before use of the requested therapy.

Requirement applies to ZTlido and Gen7T patches only.
The alternatives must include formulary/preferred options and generic non-formulary drugs with a matching member indication.

Documentation Required

Supporting Medical Records

Submit supporting medical records and any requested clinical documentation for coverage review. Records may include patient records, test results, and credentials of the provider ordering or performing the drug or service.

Provide patient records and relevant test results.
Supply provider credentials when requested.

Documentation Required

Diagnosis and Formulary Trial Documentation

Document a qualifying diagnosis of post-herpetic neuralgia, cancer-related neuropathy, or diabetic neuropathy, together with the required preferred topical therapy trial and failure or an eligible allergy or contraindication.

Document the diagnosis in the medical record.
Document adequate trial and failure of a preferred formulary topical dosage form, or the qualifying allergy/clinical contraindication.

Documentation Required

Additional ZTlido or Gen7T Requirements

For ZTlido or Gen7T, submit documentation supporting at least one additional qualifying pathway beyond the diagnosis and preferred topical therapy requirements.

Document that all formulary/preferred alternatives and matching-indication generic non-formulary drugs were tried and failed; or
Document FDA-labeled contraindication, serious side effects, likely reduced effectiveness, or likely harm from all such alternatives; or
Document that the member is currently receiving the requested medication and is at medical risk if therapy changes.

Documentation Required

Continuation Response Documentation

For continuation requests, document improvement in pain and confirm that the member has no intolerable adverse effects or drug toxicity.

Prescriber attestation or clinical reviewer finding may support the absence of intolerable adverse effects or toxicity.
Document positive clinical response as demonstrated by improvement in pain.

Unsupported block type: denial_risk亡

Documentation Required

Additional ZTlido or Gen7T Pathways

For ZTlido or Gen7T requests, document at least one qualifying additional pathway: failure of all specified alternatives, contraindication or serious adverse effects/expected harm from all specified alternatives, or medical risk from changing current therapy.

The documentation must address both formulary/preferred alternatives and generic non-formulary drugs with a matching indication.
A current-therapy exception requires documentation of medical risk if therapy changes.

Denial Risk

Insufficient Supporting Documentation

Requests may be denied when submitted documentation does not support medical necessity, non-investigational status, eligibility under the member’s benefits, or appropriate billing and practice.

Additional documentation may be requested, including patient records, test results, and provider credentials.
Payment may be denied or other action taken when records do not support the coverage determination or indicate inappropriate or excessive billing.

Denial Risk

Other Uses Are Experimental or Investigational

All other uses of lidocaine patch are considered experimental or investigational and are subject to the applicable off-label policy.

Non-policy indications are not supported as covered uses under this policy.

Denial Risk

Contraindicated Hypersensitivity

Coverage may be denied when the member has hypersensitivity to lidocaine, any component of the formulation, or another local anesthetic of the amide type.

Screen for hypersensitivity to lidocaine or formulation components.
Screen for hypersensitivity to another amide-type local anesthetic.

Billing Rule

Improper Billing or Noncovered Benefit

Claims may be rejected or payment may be recovered when lidocaine patch is billed incorrectly or is not a covered benefit. Listing or submitting a code does not guarantee coverage; providers must use industry-standard coding practices and verify benefit coverage.

Codes in the policy are for reference and may not be all-inclusive or applicable to every state or line of business.
Deleted or ineffective codes may not be eligible for reimbursement.
The payer may reject or deny the claim and recover payment when billing is inappropriate or the service is not a covered benefit.

Compendial approved off-labeled uses

DefinitionCancer-related neuropathy and diabetic neuropathy are identified as compendial approved off-labeled uses of lidocaine patch.

Use 1Cancer-related neuropathy

Use 2Diabetic neuropathy

This criterion applies only to ZTlido and Gen7T patches.